Man Group plc Invests $289,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

Man Group plc acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 9,589 shares of the biopharmaceutical company's stock, valued at approximately $289,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Arizona State Retirement System boosted its stake in shares of TG Therapeutics by 0.9% in the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock worth $1,283,000 after buying an additional 364 shares during the last quarter. Blue Trust Inc. increased its stake in TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 371 shares during the last quarter. Summit Investment Advisors Inc. increased its stake in TG Therapeutics by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock worth $440,000 after acquiring an additional 463 shares during the last quarter. New York State Teachers Retirement System grew its stake in shares of TG Therapeutics by 1.9% during the fourth quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company's stock valued at $1,317,000 after buying an additional 837 shares during the last quarter. Finally, Quadrant Capital Group LLC grew its stake in TG Therapeutics by 137.1% in the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after purchasing an additional 975 shares in the last quarter. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Trading Up 1.6%

Shares of TG Therapeutics stock traded up $0.57 during trading hours on Thursday, hitting $35.71. The company's stock had a trading volume of 1,404,000 shares, compared to its average volume of 2,974,657. TG Therapeutics, Inc. has a twelve month low of $15.16 and a twelve month high of $46.48. The firm has a fifty day moving average of $37.55 and a 200-day moving average of $34.40. The stock has a market cap of $5.67 billion, a price-to-earnings ratio of -357.06 and a beta of 2.21. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $120.86 million for the quarter, compared to analysts' expectations of $117.07 million. During the same quarter last year, the company earned ($0.07) EPS. TG Therapeutics's revenue for the quarter was up 90.4% compared to the same quarter last year. Research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analyst Upgrades and Downgrades

TGTX has been the subject of a number of analyst reports. HC Wainwright restated a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. Wall Street Zen raised TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, TG Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $40.80.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.